Your browser doesn't support javascript.
loading
Quasi-experimental evaluation of a financial incentive for first-dose COVID-19 vaccination among adults aged ≥60 years in South Africa.
Chetty-Makkan, Candice Maylene; Thirumurthy, Harsha; Bair, Elizabeth F; Bokolo, Simamkele; Day, Candy; Wapenaar, Korstiaan; Werner, Jesse; Long, Lawrence; Maughan-Brown, Brendan; Miot, Jacqui; Pascoe, Sophie J S; Buttenheim, Alison M.
Afiliação
  • Chetty-Makkan CM; Research, Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa cchetty@heroza.org.
  • Thirumurthy H; Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Bair EF; Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Bokolo S; Research, Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
  • Day C; DG Murray Trust, Cape Town, South Africa.
  • Wapenaar K; Genesis Analytics, Johannesburg, South Africa.
  • Werner J; Genesis Analytics, Johannesburg, South Africa.
  • Long L; Research, Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
  • Maughan-Brown B; Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.
  • Miot J; Southern Africa Labour and Development Research Unit, University of Cape Town, Cape Town, South Africa.
  • Pascoe SJS; University of Cape Town, Rondebosch, South Africa.
  • Buttenheim AM; Research, Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
BMJ Glob Health ; 7(12)2022 12.
Article em En | MEDLINE | ID: mdl-36543383
ABSTRACT

INTRODUCTION:

COVID-19 vaccination coverage in South Africa (RSA) remains low despite increased access to vaccines. On 1 November 2021, RSA introduced the Vooma Voucher programme which provided a small guaranteed financial incentive, a Vooma Voucher redeemable at grocery stores, for COVID-19 vaccination among older adults, a population most vulnerable to serious illness, hospitalisation and death. However, the association of financial incentives with vaccination coverage remains unclear.

METHODS:

We evaluated the association of the conditional economic incentive programme with first-dose vaccination rates among adults (aged ≥60 years) through a quasi-experimental cohort study. The Vooma Voucher programme was a nationwide vaccination incentive programme implemented for adults aged ≥60 years from 1 November 2021 to 28 February 2022. We ran ITS models to evaluate the Vooma Voucher programme at national and provincial levels. We used data between 1 October 2021 and 27 November 2021 in models estimated at the daily level. Individuals who received their first vaccine dose received a text message to access a ZAR100 ($~7) voucher that was redeemable at grocery stores.

RESULTS:

The Vooma Voucher programme was associated with a 7.15%-12.01% increase in daily first-dose vaccinations in November 2021 compared with late October 2021. Overall, the incentive accounted for 6476-10 874 additional first vaccine doses from 1 November to 27 November 2021, or 8.31%-13.95% of all doses administered to those aged ≥60 years during that period. This result is robust to the inclusion of controls for the number of active vaccine delivery sites and for the nationwide Vooma vaccination weekend initiative (12 November to 14 November), both of which also increased vaccinations through expanded access to vaccines and demand creation activities.

CONCLUSIONS:

Financial incentives for COVID-19 vaccination led to a modest increase in first-dose vaccinations among older adults in RSA. Financial incentives and expanded access to vaccines may result in higher vaccination coverage. TRIAL REGISTRATION NUMBER SANCTR DOH-27-012022-9116.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / COVID-19 Tipo de estudo: Etiology_studies / Health_economic_evaluation / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans País/Região como assunto: Africa Idioma: En Revista: BMJ Glob Health Ano de publicação: 2022 Tipo de documento: Article País de afiliação: África do Sul

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / COVID-19 Tipo de estudo: Etiology_studies / Health_economic_evaluation / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans País/Região como assunto: Africa Idioma: En Revista: BMJ Glob Health Ano de publicação: 2022 Tipo de documento: Article País de afiliação: África do Sul